KraneShares Electric Vehicles and Future Mobility vs Smith & Nephew plc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.53, while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| KARS | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $38.70 |
52-Week Low | $25.59 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.86, up 2.51% today, with a bullish technical signal but bearish moving averages. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. The stock shows strong momentum with RSI_6 at 80.23 indicating overbought conditions, while support and resistance cluster around $30-$31.
The outlook for KARS is mixed; positive EV industry trends support growth, but high RSI suggests near-term pullback risk. Investment opportunity lies in global EV expansion, while risks include U.S. market hesitation and competitive pressures from Chinese automakers.
No Aura AI signal available yet.
Trailing returns across standard periods
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →